Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Abstract C49: A population-based study from Royal Marsden Hospital (RMH) of mutational analysis and response to therapy in primary resected and locally advanced or metastatic gastrointestinal stromal tumor (GIST).

Joanna Vitfell-Pedersen, David Olmos, David Gonzalez-De-Castro, Khin Thway, Rebecca Watkins, Omar Al-Muderis, Anders Krarup-Hansen, Michelle Scurr, Charlotte Benson, Ian Judson

Mol Cancer Ther (2011) 10 (11_Supplement): C49.

https://doi.org/10.1158/1535-7163.TARG-11-C49

Published: 12 November 2011

View article titled, Abstract C49: A population-based study from Royal Marsden Hospital (RMH) of mutational analysis and response to therapy in primary resected and locally advanced or metastatic gastrointestinal stromal tumor (GIST).

Journal Articles

BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors

Udai Banerji, Annette Affolter, Ian Judson, Richard Marais, Paul Workman

Mol Cancer Ther (2008) 7 (4): 737–739.

https://doi.org/10.1158/1535-7163.MCT-08-0145

Published: 15 April 2008

View article titled, BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors

Journal Articles

Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent administered as an infusion over 24 h every 21 days in patients with solid tumors

Richard Baird, Andre Planting, Alison Reid, Jos Kitzen, Sarah Reade, Paul Clarke, Lyndsey Welsh, Luis Lopez Lazaro, Begona de las Heras, Ian Judson, Cesar Pico, Paul Workman, Ferry Eskens, Stan Kaye, Johann de Bono, Jaap Verweij

Mol Cancer Ther (2007) 6 (11_Supplement): A141.

Published: 01 November 2007

View article titled, Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent administered as an infusion over 24 h every 21 days in patients with solid tumors

Journal Articles

A phase I trial of the heat shock protein 90 (HSP90) inhibitor alvespimycin (17-dimethylaminoethylamino-17-demethoxygeldanamycin 17-DMAG) administered weekly, intravenously, to patients with advanced, solid tumors

Simon Pacey, Richard Wilson, Mike Walton, Eatock Martin, Javier Moreno-Farre, Hendrik-Tobias Arkenau, Heidi Steinfeldt, Florence Raynaud, Paul Workman, Ian Judson

Mol Cancer Ther (2007) 6 (11_Supplement): PR-6.

Published: 01 November 2007

View article titled, A phase I trial of the heat shock protein 90 (HSP90) inhibitor alvespimycin (17-dimethylaminoethylamino-17-demethoxygeldanamycin 17-DMAG) administered weekly, intravenously, to patients with advanced, solid tumors

Journal Articles

^{Clinical outcome and prognostic factors for patients treated within the context of a phase I study: The Royal Marsden Hospital (RMH) experience.}

Hendrik-Tobias Arkenau, Joo Ern Ang, David Olmos, Craig Carden, Sophie Postel-Vinay, Debs Sarker, Claire Barlow, Johann de Bono, Ian Judson, Stan Kaye

Mol Cancer Ther (2007) 6 (11_Supplement): A154.

Published: 01 November 2007

View article titled, Clinical outcome and prognostic factors for patients treated within the context of a phase I study: The Royal Marsden Hospital (RMH) experience.

Journal Articles

A phase I study of the safety, tolerability and antitumor activity of escalating doses of combretastatin A4 phosphate (CA4P) given in combination with bevacizumab to subjects with advanced solid tumors

Paul Nathan, Ian Judson, Anwar Padhani, Adrian Harris, Rajesh Sinha, Boxall Jane, Jon Smythe, Nita Fisher, Jane Taylor, David Collins, Hillori Connors, Rustin Gordon

Mol Cancer Ther (2007) 6 (11_Supplement): B7.

Published: 01 November 2007

View article titled, A phase I study of the safety, tolerability and antitumor activity of escalating doses of combretastatin A4 phosphate (CA4P) given in combination with bevacizumab to subjects with advanced solid tumors

NARROW

Abstract C49: A population-based study from Royal Marsden Hospital (RMH) of mutational analysis and response to therapy in primary resected and locally advanced or metastatic gastrointestinal stromal tumor (GIST).

BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors

Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent administered as an infusion over 24 h every 21 days in patients with solid tumors

A phase I trial of the heat shock protein 90 (HSP90) inhibitor alvespimycin (17-dimethylaminoethylamino-17-demethoxygeldanamycin 17-DMAG) administered weekly, intravenously, to patients with advanced, solid tumors

^{Clinical outcome and prognostic factors for patients treated within the context of a phase I study: The Royal Marsden Hospital (RMH) experience.}

A phase I study of the safety, tolerability and antitumor activity of escalating doses of combretastatin A4 phosphate (CA4P) given in combination with bevacizumab to subjects with advanced solid tumors

Email alerts

AACR Journals

Abstract C49: A population-based study from Royal Marsden Hospital (RMH) of mutational analysis and response to therapy in primary resected and locally advanced or metastatic gastrointestinal stromal tumor (GIST).

BRAF and NRAS mutations in melanoma: potential relationships to clinical response to HSP90 inhibitors

Phase I safety, pharmacokinetic, and pharmacogenomic trial of ES-285, a novel marine cytotoxic agent administered as an infusion over 24 h every 21 days in patients with solid tumors

A phase I trial of the heat shock protein 90 (HSP90) inhibitor alvespimycin (17-dimethylaminoethylamino-17-demethoxygeldanamycin 17-DMAG) administered weekly, intravenously, to patients with advanced, solid tumors

Clinical outcome and prognostic factors for patients treated within the context of a phase I study: The Royal Marsden Hospital (RMH) experience.

A phase I study of the safety, tolerability and antitumor activity of escalating doses of combretastatin A4 phosphate (CA4P) given in combination with bevacizumab to subjects with advanced solid tumors

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only

^{Clinical outcome and prognostic factors for patients treated within the context of a phase I study: The Royal Marsden Hospital (RMH) experience.}